Kiadis Pharma
Zernikepark 6-8
Groningen
9747 AN
Tel: 31-0-50-547-42-70
Fax: 31-0-50-547-42-71
Website: http://www.kiadis.com/
Email: info@kiadis.com
78 articles about Kiadis Pharma
-
One Year Data From Kiadis Pharma's Ongoing Phase II Trial With ATIR101 Will Be Presented At American Society of Hematology 2016 Annual Meeting
11/3/2016
-
Kiadis Pharma Announces Financial Results For The Six Months Ended June 30, 2016
8/26/2016
-
Kiadis Pharma Notice Of Results For The Six Months Ended 30 June 2016
8/19/2016
-
Kiadis Pharma And The Leukemia & Lymphoma Society Strengthen Partnership Around The Development Of ATIR101 In ALL And AML Patients
7/11/2016
-
Kiadis Pharma’s Orphan Drug Designation For ATIR101 Further Expanded To Include Treatment In A Hematopoietic Stem Cell Transplantation
6/30/2016
-
Kiadis Pharma Announces Result Of Annual General Meeting
6/28/2016
-
Kiadis Pharma Appoints PCT As Its Contract Manufacturing Organization In The United States
6/21/2016
-
Kiadis Pharma Announces Its Decision To File For Marketing Authorization With European Medicines Agency For ATIR101 In Blood Cancers
6/2/2016
-
Kiadis Pharma Presents Multiple Sets Of Data At The International Society For Cellular Therapy (ISCT) 2016 Annual Meeting
5/18/2016
-
Kiadis Pharma Announces Annual Results For The Year Ended 31 December 2015
4/15/2016
-
Kiadis Pharma Proposes Robert Soiffer And Berndt Modig As Its New Supervisory Board Members
4/7/2016
-
Kiadis Pharma Presents Positive Data On The Primary Endpoint Of Its Single Dose Phase II Trial With ATIR101
4/4/2016
-
Kiadis Pharma To Host A Webcast Of The Full Dataset On The Primary Endpoint Of Its Single-Dose Phase II Trial With ATIR101
3/29/2016
-
Kiadis Pharma Satellite Symposium At 42nd Annual Meeting Of The European Society For Blood And Marrow Transplantation
3/14/2016
-
Top-Line Data From All Patients On The Primary Endpoint Of Kiadis Pharma’s Phase II Trial With ATIR101 Selected For Oral Presentation At 42nd Annual Meeting Of The European Society For Blood And Marrow Transplantation
3/1/2016
-
Kiadis Pharma And The Leukemia & Lymphoma Society Enter Partnership For The Development Of ATIR101 In ALL And AML Patients
2/1/2016
-
Kiadis Pharma Announces A Global Collaboration With The Thalassaemia International Federation
12/21/2015
-
Kiadis Pharma Utilizes BioLife Solutions, Inc. HypoThermosol To Improve Viability And Shelf Life Of Donor Leukocytes In Clinical Trial Of ATIR101 T Cell Therapy For Blood Cancers
10/19/2015
-
European Medicines Agency Grants Kiadis Pharma's Lead Product ATIR ATMP Certificate For Quality And Non-Clinical Data
5/13/2015
-
Kiadis Pharma Appoints Dr. Vincent Brichard To Its Supervisory Board
5/7/2015